124465-55-0

Upstream product

• 109723-39-9 1-benzoyl-5-bromo-1,2,2a,3,4,5-hexahydro-benzo[cd]indole 
• 65229-90-5 1-benzoyl-1,2,2a,3,4,5-hexahydro-benz[cd]indol-5-ol 
• 132008-45-8 1-benzoyl-2,2a,3,4-tetrahydro-1H-benz[cd]indol-5-one 

Downstream Products

• 157649-33-7 1-benzoyl-1,2,2a,3,4,5-hexahydro-benz[cd]indole 
• 39890-59-0 Phenyl-(5aS,6aS,7aR)-5a,6,6a,7a-tetrahydro-5H-7-oxa-4-aza-cyclopropa[e]acenaphthylen-4-yl-methanone 
• 39890-59-0 Phenyl-(5aS,6aR,7aS)-5a,6,6a,7a-tetrahydro-5H-7-oxa-4-aza-cyclopropa[e]acenaphthylen-4-yl-methanone 
• 124465-73-2 ((2aS,4S,5R)-4,5-Dihydroxy-2a,3,4,5-tetrahydro-2H-benzo[cd]indol-1-yl)-phenyl-methanone 
• 39890-59-0 1-benzoyl-4,5-epoxy-1,2,2a,3,4,5-hexahydrobenzindole 
• 69380-12-7 4-amino-1-benzoyl-1,2,2a,3,4,5-hexahydro-benz[cd]indole 
• 134745-89-4 (3α,8α,9α,10α)-2,3-Dihydro-9-methanesulfonyloxy-8-methanesulfonyloxymethyl-1-<(4-methoxyphenyl)sulfonyl>-6-methylergoline 
• 134745-89-4 (3β,8α,9α)-2,3-Dihydro-9-methanesulfonyloxy-8-methanesulfonyloxymethyl-1-<(4-methoxyphenyl)sulfonyl>-6-methylergoline 
• 99499-50-0 Methanesulfonic acid (5aS,6aR,9R,10R,10aS)-10-hydroxy-4-(4-methoxy-benzenesulfonyl)-7-methyl-4,5,5a,6,6a,7,8,9,10,10a-decahydro-indolo[4,3-fg]quinolin-9-ylmethyl ester 
• 99499-50-0 (3β,8α,9α)-2,3-Dihydro-8-methanesulfonyloxymethyl-1-<(4-methoxyphenyl)sulfonyl>-6-methylergolin-9-ol 
• 89651-07-0 (3aβ,5aβ,6aα,11bα,11cβ)-5,5a,6,6a,7,8,11b,11c-Octahydro-8-<(4-methoxyphenyl)sulfonyl>-5-methylfuro<4,3-fg>quinolin-4(3aH)-one 
• 89651-07-0 (3aβ,5aα,6aα,11bα,11cβ)-5,5a,6,6a,7,8,11b,11c-Octahydro-8-<(4-methoxyphenyl)sulfonyl>-5-methylfuro<4,3-fg>quinolin-4(3aH)-one 
• 89651-07-0 (3aβ,5aβ,6aβ,11bα,11cβ)-5,5a,6,6a,7,8,11b,11c-Octahydro-8-<(4-methoxyphenyl)sulfonyl>-5-methylfuro<4,3-fg>quinolin-4(3aH)-one 
• 89651-11-6 (3α,8α,9α,10α)-2,3-Dihydro-8-hydroxymethyl-1-<(4-methoxyphenyl)sulfonyl>-6-methylergolin-9-ol 

Relevant academic research and scientific papers

Synthetic studies toward the partial ergot alkaloid LY228729, a potent 5HT(1A) receptor agonist

Synthetic studies on LY228729 (3) afforded two innovative approaches for the construction of this class of partial ergoline 5HT(1a) receptor agonists. The first synthesis is based upon a diastereoselective epoxidation of racemic olefin 5, followed by ring

4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]indole

4-(Di-n-propyl)amino-1,3,4,5-tetrahydrobenz[cd]-indole, useful as prolactin inhibitor and in treatment of Parkinsonisn.